Each seat cross-examines another seat's case. Then each one says whether it holds or changes its vote. In this meeting, 1 of 5 seats changed their vote.
The Compounder questions The Visionary Bettor
You vote GO, then admit you do not know whether you are near break-even or burning SGD 95,000 a month. That gap is the whole decision. Selling shares at a lower valuation when you cannot say what you are worth means paying with your most expensive currency for a number you have not checked. Your own working shows one version of this company barely needs money. Raising there gives away a slice of 20 years of compounding to solve a problem you may not have. Pricing power is the better asset. The March rise held, so test it on existing clinics before you sell equity. And "cuts hurt the 70%" assumes every cost drives growth. Nobody here has shown that. Find the real burn this week. Then decide. A qualified finance professional should check any terms.
Holds RESHAPEbecause nothing Seat B said answers whether the burn is gross or net, and that still decides whether a raise is needed at all.
The Visionary Bettor questions The Compounder
Seat A, you call pricing power the cheapest capital, then use it as a reason to stay small. That is the strikeout looking. The March price rise proves clinics want more of you, and the real question is who owns that demand in ten years. Equity you refused to sell is worth little if a bundled rival takes the category while you guard the cap table. The ownership that compounds sits in the company that ends up No.1, not the one that kept more of a niche. My bias is survivorship: I hear about the raises that paid, and leverage has hurt this school. So I concede your arithmetic. But if the burn turns out to be net, waiting is not thrift, it is drift. Confirm the burn this week, then raise for the curve, not for survival.
Changed vote GO to RESHAPEbecause every seat has shown the same company is either nearly break-even or clearly short of cash depending on one unknown, so the bet should be sized only after you confirm net burn, with a bridge from existing backers buying that time.
The Systems Sceptic questions The Visionary Bettor
You vote GO while admitting you do not know which company this is. You also wave away the total-costs case by saying "14 months could not be right". It can. A loss of about SGD 3,000 a month over 14 months means roughly SGD 42,000 in the bank: a thin cushion, not an error. You price the raise off ARR and 70% growth, but the Gurley test is the quality of each dollar: gross margin, how it was acquired, and what the next dollar costs. Nobody here knows any of those. Raising at a lower valuation before measuring burn sells ownership blind. "Safety you do not yet need" also quietly assumes the net case. Get one line from the accountant this week, then vote. Growth with no measured burn is a narrative without numbers.
Holds RESHAPEbecause nothing argued here tells you whether SGD 95,000 is gross or net, and every option turns on that.
The AI-Era Founder questions The Visionary Bettor
Seat B, I share your love of the curve, but your GO rests on an arithmetic slip. If SGD 95,000 is total costs, "14 months" is not impossible. It is a floor. It would mean you divided cash by gross costs, so roughly SGD 1.33m sits in the bank against a loss of a few thousand a month, and your true runway is far longer. That figure is an estimate. In that world, raising now at a lower valuation sells cheap ownership to fix nothing. My school will happily raise to ride a curve, and I own our bias: we overrate how fast clinics change. But a raise needs a stated use, such as sales or the product that cheap intelligence now makes possible. You named none. Settle the burn question this week. Then raise from strength, or bridge if the number is ugly.
Holds RESHAPEbecause the burn is still unknown, and a GO decided before you know it is a guess with paperwork attached.
The Rival questions The Visionary Bettor
You treat the March price rise as a secret. It is not. It shows clinics will pay more, and I can see that too. What I cannot see is your burn, and neither can you. Going to market now, at a lower price, while unsure whether the SGD 95,000 is a cost or a loss, hands me a gift. A cheaper round gets noticed, and my sales team will tell every clinic you serve that you are struggling. You say cutting costs threatens the team behind the 70% growth. A rushed raise threatens the same growth, because it is my best sales pitch against you. The cheapest answer is to learn the real burn this month, then raise from strength or not at all. Speed only helps you if you know which company you are.
Holds RESHAPEbecause nobody has yet settled whether the burn is gross or net, and that is what decides between a cut and a raise.